Adagio Medical Holdings, Inc. reported a significant decrease in cash and cash equivalents from $17.1 million at the end of 2025 to $3.1 million as of September 30, 2026. The company highlighted substantial risks regarding its ability to continue as a going concern and is exploring strategic alternatives to maximize stockholder value.
Adagio Medical reported Q3 2026 financial results, highlighting a net income of $17.8 million primarily driven by a $23.0 million gain from the change in fair value of warrant liabilities. The company also announced that its Board of Directors has initiated a formal process to explore strategic alternatives to maximize shareholder value while continuing clinical progress on its vCLAS Ultra System.
Term
Q3 2026
“The third quarter was defined by progress in the clinical and regulatory programs that we believe are the foundation for the value of Adagio and our ULTA platform. Our PMA application for the vCLAS Ventricular Ablation System remains under FDA review, and we initiated the vCLAS Ultra IDE study, which builds on the FULCRUM-VT results with a faster, more maneuverable next-generation catheter.”
Todd Usen, Chief Executive Officer of Adagio Medical
“As the Board’s review of strategic alternatives continues, we have aligned our cost structure around these prioritized programs and remain focused on maximizing value for our shareholders.”
Todd Usen, Chief Executive Officer of Adagio Medical
Adagio Medical Holdings, Inc. filed an amendment to its Articles of Incorporation or Bylaws (Item 5.03). This type of filing typically involves administrative changes to corporate governance or the company's fiscal year structure.
Adagio Medical Holdings stockholders approved a proposal for a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-500. The final ratio will be determined by the Board of Directors at its discretion to consolidate outstanding shares.